Three of the trials included both placebo and active control groups, while others were either placebo- or active-controlled
GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
The following sections will break down this comparison
Similarities: Both are FDA-approved Wegovy formulations Both use semaglutide as the active ingredient Both follow a gradual dose-increase schedule determined by a provider Side effects are generally similar and can be managed with provider support Differences: Wegovy pen: Taken as a once-weekly injection Wegovy pill: Taken orally once per day Your Shed provider will help determine which option may be appropriate based on your health history, preferences, and treatment goals
Decisions about whether a compound is appropriate for you, and at what dose, belong with a qualified clinician who knows your history.
Rapid improvement in glucose control has been associated with transient worsening of retinopathy, which has been observed in GLP-1 trials